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“Live as if you were to die tomorrow.  
Learn as if you were to live forever.” 
Mahatma Gandhi 
3 
 
Table of Contents 
Table of Contents ................................................................................................................. 3 
Acknowledgments ............................................................................................................... 5 
List of papers ....................................................................................................................... 6 
1 Introduction ................................................................................................................. 7 
1.1 History of Sudden infant death syndrome (SIDS) ................................................ 7 
1.1.1 Environmental risk factors – the great turn ................................................. 10 
1.1.2 Genetic risk factors ...................................................................................... 12 
1.2 SIDS definition ................................................................................................... 13 
1.3 SIDS and infection .............................................................................................. 15 
1.4 Cytokines ............................................................................................................ 19 
1.5 Pro-inflammatory cytokines ................................................................................ 19 
1.5.1 Interleukin 1α ............................................................................................... 19 
1.5.2 Interleukin 1β ............................................................................................... 20 
1.5.3 Interleukin 6 ................................................................................................. 21 
1.5.4 TNFα ............................................................................................................ 21 
1.5.5 Interleukin 8 ................................................................................................. 21 
1.5.6 Interleukin 12 ............................................................................................... 22 
1.5.7 Interleukin 18 ............................................................................................... 22 
1.5.8 IFN-γ ............................................................................................................ 23 
1.6 Anti-inflammatory cytokines .............................................................................. 23 
1.6.1 Interleukin 13 ............................................................................................... 23 
1.6.2 Interleukin 16 ............................................................................................... 24 
1.6.3 Interleukin 1ra .............................................................................................. 24 
1.7 Genetic variations ............................................................................................... 24 
1.7.1 Mutations ..................................................................................................... 24 
1.7.2 Polymorphisms ............................................................................................ 25 
2 Previous studies on SIDS and polymorphisms in genes involved in the immune 
system ................................................................................................................................ 27 
3 Aims of the study ....................................................................................................... 29 
4 Material and methods ................................................................................................ 30 
4.1 Subjects ............................................................................................................... 30 
4.2 Bioinformatics ..................................................................................................... 31 
4.3 DNA extraction ................................................................................................... 32 
4.4 DNA quantification ............................................................................................. 33 
4.5 Sequenom® multiplex ........................................................................................ 34 
4.6 TaqMan genotyping ............................................................................................ 37 
4.7 Sequencing .......................................................................................................... 38 
4.8 Construction of SNP profiles and VNTR/SNP combinations ............................ 38 
4.9 Allele specific PCR ............................................................................................. 38 
4.10 VNTR analyses ............................................................................................... 39 
4.11 Gel electrophoresis .......................................................................................... 40 
4.12 Immunohistochemistry, HLA-DR ................................................................... 40 
4.13 Statistical analyses ........................................................................................... 41 
4.14 Registry and approval ...................................................................................... 41 
5 Summary of papers .................................................................................................... 42 
5.1 Paper I ................................................................................................................. 42 
5.2 Paper II ................................................................................................................ 43 
5.3 Paper III .............................................................................................................. 44 
4 
 
5.4 Paper IV .............................................................................................................. 45 
6 General discussion ..................................................................................................... 46 
6.1 Selection of genetic variations ............................................................................ 46 
6.2 Methodological challenges ................................................................................. 46 
6.3 Multiple comparisons .......................................................................................... 49 
6.4 Hardy Weinberg equilibrium .............................................................................. 50 
6.5 Inter- and intraobserver variation in the histopathological evaluation ............... 50 
6.6 The fatal triangle ................................................................................................. 51 
6.7 Cytokine gene polymorphisms and its possible role in SIDS ............................. 54 
7 Conclusion ................................................................................................................. 55 
8 References ................................................................................................................. 56 
9 Errata ......................................................................................................................... 68 
 
 
 
 
 
 
 
 
 
 
 
 
5 
 
 
Acknowledgments  
This thesis is based on studies carried out at the Institute of Forensic Medicine, 
University of Oslo, during the years 2007-2010. I would like to thank the institute for 
providing me with great work facilities and the high standard analytical technology 
necessary to complete the research.  
This research project would not have been possible without the support of many 
people. I would like to express my sincere gratitude to my supervisor, Dr Siri Hauge 
Opdal who has been abundantly helpful and offered invaluable assistance, support 
and guidance as well as constructive reviews of the original manuscripts. My deepest 
gratitude are also due to my co-supervisors professor Torleiv Ole Rognum and 
professor Åshild Vege for introducing me to the scientific thinking in the field of 
forensic genetics, without whose knowledge and assistance this study would not have 
been successful. The supervisors have all encouraged and challenged me throughout 
my academic program. They have guided me through the dissertation process, never 
accepting less than my best efforts and always been available to help and support me 
and shared their invaluable experience and immense knowledge in the field of 
forensic medicine. I thank them all. 
I would also like to express my deepest appreciation to the technical support 
provided by colleagues and staff at the institute. In particular thanks to Margrethe 
Abildgaard, Hang Duong, Musse Ahmed Musse and Sara Moberg for outstanding 
laboratory skills and enthusiastic approaches to new challenges. I would also express 
my gratitude to Anne Gunn Winge and Anne Lise Lunde for their enormous effort 
and personalized attention to all the administrative challenges, and for being such 
good friends and colleagues, its is highly appreciated.    
I am grateful to the Norwegian SIDS and Stillbirth Society and the Norwegian 
ExtraFoundation  for Health and Rehabilitation for acknowledging the importance of 
this research and providing financial support.  
A special thanks to my wonderful father, for his unlimited support through out my 
academic career and his unconditional love and encouragement. Not forgetting my 
sister that has always been there for me every step on the way. And finally, my 
darling daughter for always being so flexible and understanding during hectic work 
periods, never complaining and always being such a joy for me, thank you. 
6 
 
List of papers  
This thesis is based on the following papers: 
I. Ferrante L, Opdal SH, Vege Å, Rognum TO. TNF-α promoter polymorphisms 
in sudden infant death. Hum Immunol 2008; 69:368-73.  
II. Ferrante L, Opdal SH, Vege Å, Rognum TO Cytokine gene polymorphisms 
and sudden infant death syndrome. Acta Paediatr. 2010; 99:384-8.   
III. Ferrante L, Opdal SH, Vege Å, Rognum TO. IL-1 gene cluster 
polymorphisms and sudden infant death syndrome. Hum Immunol 2010; 
71:402-6.   
IV. Ferrante L, Opdal SH, Vege Å, Rognum TO. Is there any correlation between  
HLA-DR expression in laryngeal mucosa and interleukin gene variation in 
sudden infant death syndrome? Submitted.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7 
 
1 Introduction 
1.1 History of Sudden infant death syndrome (SIDS) 
For centuries sudden infant death syndrome (SIDS) has been a subject of mystery and 
superstition. It has been known for at least 3000 years, and is mentioned in the Bible. 
Unexpected child death was thought to be caused by overlaying during the times of 
King Solomon. The biblical tale describes two women who lived in the same house, 
both had a son. One night one of the boys died because the mother had laid on him. 
She quickly changed her dead boy with the live boy of the other woman. As they 
woke up the women started to quarrel about which of them that was the mother of the 
live child. They brought their case to King Solomon who acted as if he was to cut the 
boy in two pieces so that each women could receive one half of the baby. When the 
women heard this verdict one of them cried out “Please, My Lord, give her the live 
child - do not kill him!” while the other woman replied "It shall be neither mine nor 
yours - divide it!". The king then realized that the true mother was trying to save the 
child and gave her the baby (figure 1) (1).   
 
Figure 1: King Solomon passing judgment on who is the rightful mother to the baby. 
Source: Nineteenth century engraving by Gustave Doré.    
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To avoid such situations, the Greek physician Soranus of Ephesus wrote in the first 
medical textbook instruction to the mothers not to share bed with their babies. The 
theory of overlaying remained the only explanation for SIDS in centuries.  
In the late 1800s and early 1900s physicians was convinced that cot death was 
caused by a pathologically enlarged thymus which would inflict internal suffocation.  
It was believed that the enlarged thymus could asphyxiate the child from inside (2). 
To prevent suffocation the infants were radiated to reduce the thymus size. This gave 
an immediate reduction, but within days it retained its normal size. This theory was 
widely accepted and referred to as status thymolymphaticus, and was not rejected 
until the 1940s, when it was discovered that a large thymus represents a normal 
developmental stage (3).  
In the 1950s the trend shifted and a paper claiming viral and bacterial 
inflammation in the upper airways as a cause of death was published (4). This study 
investigates 26 infants below 12 months of age whose death was observed by an 
adult. In ten of the cases the gross autopsy findings were sufficient to explain death; 
nine cases died due to a heart disease while in one case interstitial bronchopneumonia 
was found (4). In the 16 cases were gross autopsy findings were inconclusive, 
microscopic investigations revealed that bronchitis was present in 11 of the 16 cases 
(4). Using current diagnostic criteria, most likely some of these 16 cases would be 
given a diagnosis of SIDS. Another theory was hypogammaglobulinemia (5). Spain 
and coworkers measured postmortem serum gamma globulin in three infants who 
died suddenly and unexpectedly, and found that these infants had low gammaglobulin 
levels compared to infant controls (5). However, this assumption was made based on 
very few observations, with only three cases and two controls. A larger study later 
that decade did not reproduce the findings, but showed similar levels of gamma 
globulin in babies found dead suddenly and unexpectedly as well as in healthy babies 
(6). 
The 1960s was the decade when researchers proposed that the cause of sudden 
infant death was hypersensitivity to cow’s milk (7). They claimed that these infants 
had elevated levels of antibodies to cow’s milk in their sera, and showed that guinea 
pigs with similar levels of antibodies could be killed by an anaphylactic reaction by 
introducing a small amount of milk in their pharynx. However, Gold et al was unable 
to confirm the finding (8), and the hypothesis was soon abandon.  
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In 1969 the “syndrome” was introduced by Beckwith (9) and the term sudden 
infant death syndrome - SIDS - was given its ICD code (798). During the 1970s much 
focus in SIDS research was directed towards the apnea theory (10). Several prominent 
researchers investigated this theory, and in 1972 Steinschneider published a study in 
which he claimed that the prolonged apnea was part of the final death mechanism in 
SIDS (11).  As a result of this research apnea monitors were developed and 
distributed world wide, as an attempt to prevent SIDS. However, it later appeared that 
two of the five infants described by Steinschneider as dying from SIDS after episodes 
with apneas in fact were homicides.  
Naeye investigated a wide range of tissue specimens from SIDS victims and age 
matched controls, and found seven tissue markers for hypoxia and hypoxemia 
significantly more frequent in SIDS than in controls (12). These were hypertrophy 
and hyperplasia of the smooth muscular media in the walls of the small pulmonary 
arteries, right ventricular hypertrophy of the heart, prolonged retention of periadrenal 
brown fat, excessive production of red blood cells in the liver, hyper- or hypoplasia of 
glomic tissue in the carotid body, hyperplasia of chromaffin tissue in the adrenal 
medulla, and brain stem scarring. Three of these markers were later verified by other 
researchers; excess of brown fat around the adrenals, excessive production of red 
blood cells in the liver and scarring in the brain stem (13, 14). The latter observation 
was confirmed in a multi center study (15). Astrogliosis of the brainstem has been 
confirmed by several research groups whereas some groups have not been able to 
reproduce the findings (16). Interestingly, in a series of SIDS cases from the Institute 
of Forensic Medicine in Oslo, astrogliosis of the brain stem was associated with 
maternal smoking during pregnancy (17, 18).  
The presence of brainstem astrogliosis may also point to episodes of hypoxia after 
birth but prior to the fatal event. Since this tissue markers takes several days to 
develop their presence cannot throw light on the period immediately prior to death. 
Thus, the discovery of increased hypoxanthine levels in vitreous humor of SIDS 
victims attracted much attention (19). Hypoxanthine is a biochemical marker of 
hypoxia and indicates that a large proportion of SIDS victims have had repeated 
hypoxic episodes immediately prior to death (20). Evidence of antecedent hypoxia is 
further substantiated by Jones et al in 2003 by demonstrating increased concentrations 
of vascular endothelial growth factor (VEGE) in the cerebrospinal fluid (CSF) in 
SIDS victims (21).  
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In the 1980s morphological studies of the central nervous system in SIDS victims 
were given priority. The hypothesis of immature neuronal respiratory control in SIDS 
were proposed by Quattrochi et al in 1980 (22). Hannah Kinney’s research group 
demonstrated delayed myelinization in brains from SIDS victims (23). In the late 
eighties a large epidemiological study was performed by NICHD were several risk 
factors were introduced, among them were low birth weight, illness after birth and 
lack of sufficient medical care (24). As a result of this study, NICHD in 1993 
published  the Histophatological Atlas of the sudden infant death as a tool to 
standardize the diagnosis (25). In the Nordic countries a similar approach was 
initiated by the Nordic council of ministers (26, 27). In the Nordic study (Nord-SIDS) 
focus were on risk factors as prone sleeping, smoking, warm environment and on 
standardizing the SIDS diagnostic.  
 
1.1.1 Environmental risk factors – the great turn   
The dominating discovery in the early 1990s was the dramatic decline in SIDS deaths 
reported from countries all over the world when the babies were put to sleep supine 
instead of prone (28-31). This was based on discoveries done in the late 1970s, when 
dr. Tonkin in New Zealand and dr. Beal in Australia visited families that had lost 
infants in SIDS and learned that the main common feature was that the babies had 
slept prone (32-34). In January 1990 a Norwegian pediatrician, professor Markestad 
from the university of Bergen, issued a written advice against a prone sleeping 
position. In the late 80’s 65% of all infants had been put to sleep prone, eight months 
after Markestad gave the new instruction, prone sleeping was drastically reduced to 
only 7% of the infants (35). The effect on the Norwegian SIDS rates was immense 
(fig. 2), the rate in 1991 being 50 % lower then the 1989 rate (fig. 2)  
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Figure 2: SIDS-rate in the Nordic countries 1977-2008.  The campaign to turn the babies 
from prone to supine sleeping was in Norway initiated by professor Trond Markestad in 
Bergen at the end of 1989, and was introduced in the other Nordic countries in March 
1990. The effect was dramatic (36).  
 
Kohler and Markestad stressed that the information to parents should focus on 
three well known risk factors; parental smoking, prone sleeping position and ambient 
temperature (37). Markestad also reported the effect on this type of information and 
showed that within only a few months the parents and caregivers were now putting 
their babies to sleep on their back (38). In 1992, the American Academy of Pediatrics 
in USA issued a recommendation that infants with no medical complications should 
be put to sleep on their side or their back (39).  
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1.1.2 Genetic risk factors  
Another research area that received a lot of attention during the 1990’s was an  
observation made already in the 80s on the enzyme medium chain acylcoenzyme A 
dehydrogenase (MCAD). MCAD is an enzyme involved in the β oxidation of fatty 
acids in mitochondria. A case report from Sheffield describes an 18 month old boy 
that first was thought to be a SIDS victim, but after screening for this enzyme 
deficiency it was found that the boy suffered from MCAD- deficiency (40). The most 
common disease causing mutation in the MCAD gene is the A985G, and this 
mutation have been investigated in SIDS populations all over the world (41-49). 
However, the G985 allele does not seem to be overrepresented in SIDS.  
Besides MCAD, the gene encoding complement component C4 was one of the 
first genes to be investigated with regard to SIDS (50-52). The gene consists of two 
loci, C4A and C4B, that are highly polymorphic, and even a partial deletion of one of 
the alleles may cause an immune response that is not able to neutralize bacteria 
adequately. Studies from Norwegian and German SIDS populations did however not 
uncover any association between SIDS and C4 deletion, but both studies report an 
association between partial deletions of the C4 gene and a history of slight infection 
prior to death in SIDS (50-52).    
During the last decade SIDS research has been increasingly focused on the study 
of genetic predisposing factors, and so far genes involved in the regulation of the 
immune system, cardiac function, the serotonergic network and brain function and 
development have emerged as the most important with regard to SIDS (53). Various 
mutations and polymorphisms in these genes have been found associated with SIDS, 
but so far only mutations in genes involved in long QT syndrome (LQTS) may be 
viewed as independent cause of death. Concerning the other possible genetic 
predispositions to SIDS, they are most likely part of a polygenic inheritance pattern, 
contributing to triggering a death mechanism when combined with environmental risk 
factors, such as maternal smoking, prone sleeping position or infection.  
Long QT syndrome (LQTS) is a genetically heterogeneous cardiac disorder that is 
caused by mutations in several genes coding for ion channels, including KCNQ1, 
KCNH2, SCN5A, KCNE1, KCNE2, KCNJ2 and CAV3. The rationale for 
investigating LQTS genes in SIDS is based on a study by  Schwartz et al. They 
screened over 30 000 newborns with a one year prospective follow-up, and found that 
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prolonged QT interval in the first week of life was strongly associated with sudden 
infant death (54). A large study of 201 Norwegian SIDS cases demonstrated that 
9.5%  of cases diagnosed as SIDS carried functionally significant genetic variants in 
the LQT genes, indicating that sudden arrhythmic death is an important contributor to 
the group of sudden unexpected deaths in infants (55).  The most commonly observed 
mutation was in the SCN5A gene, which is of particular interest since mutation in this 
gene is known to cause arrhythmias during sleep, when most SIDS deaths occur. Due 
to the finding of LQTS mutations in SIDS the autopsy protocol in Oslo was extended 
to include screening of LQTS genes. Consequently, infants with such genetic disorder 
are not included in the SIDS group.   
 
Table 1: Changes in SIDS research interest over decades  
Time  Hypothesis  
Bible  Maternal overlaying  
1890 Thymolymphaticus  
1950 Hypogammaglobulemia  
1960 Hypersensitivity to milk 
1970 Apnea 
1980 Tissue- and biochemical markers for hypoxia  
1990 Prone sleeping/environmental risk factors, 
immunological “overreaction” 
2000- Seretonergic imbalance, Genetic risk factors 
 
1.2 SIDS definition  
The first SIDS definition was established during the conference in 1969, initiated by 
the National institute of Child Health and Human Development (NICHD). The 
purpose was to form a consensus for a common classification, and resulted in the 
definition formulated by Beckwith: “The sudden death of any infant or young child, 
which is unexpected by history, and in which a thorough post mortem examination 
fails to demonstrate an adequate cause of death” (9) 
The most widely used definition for SIDS today is the San Diego definition, 
which was approved at the 8th SIDS International Conference, in Edmonton, Canada, 
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in 2004. According to this definition, SIDS “ is defined as the sudden unexpected 
death of an infant under 1 year of age, with onset of the fatal episode apparently 
occurring during sleep, that remains unexplained after a thorough investigation that 
includes carrying out a complete autopsy and review of the circumstances of death 
and the clinical history” (56).  
This definition divides SIDS into three categories. These are named category I 
and II SIDS and in addition there is a category for unclassified SIDS. The definition 
have detailed requirements for autopsy findings, clinical history and circumstances of 
death.  
Category I SIDS includes infants that meet the general definition and are between 
the age of 21 days and 9 months, and this category also requires a full term pregnancy 
and normal growth. Investigation of the scene were the baby was found dead is 
required, in order to rule out any environmental cause of death. A post mortem 
examination must be performed, and no pathological findings or any sort of trauma 
that might explain death must be uncovered. Likewise, there must be negative 
toxicology.  
The category II SIDS includes the infants that meet the category I criteria except 
one or more of the following; age range outside category I, similar deaths in near 
family, neonatal or perinatal conditions as for example premature birth, circumstances 
of  death not clarified and findings at autopsy.   
The unclassified SIDS is the cases in which the category I and II were not met, or 
an alternative diagnosis is equivocal. Infants that did not undergo a post mortem 
examination will also be included in this category. Many forensic pathologist have 
great doubt about the latter category – giving the case a SIDS diagnosis without 
performing a post mortem examination. The fact that in genuine SIDS recent studies 
only comprise approximately 40% of the infants that suffer sudden unexpected 
deaths, makes it even more important to perform an autopsy (57) .   
The diagnostic criteria used in SIDS diagnostic vary worldwide, providing a 
challenge to researchers. This fact makes it difficult to compare SIDS rates between 
countries and to perform international collaboration studies including different SIDS 
populations. Due to the high SIDS rate in the Nordic countries during the 80’ties, 
especially in Norway and Denmark, a Nordic SIDS study was initiated by the Nordic 
Council of Ministers (27). As part of this NORD SIDS study forensic pathologists 
from all Nordic countries gathered and developed a protocol for the classification of 
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SIDS. There were three categories, pure SIDS, borderline SIDS and non-SIDS. To 
meet the diagnostic criteria for pure SIDS the autopsy and clinical information must 
not reveal any pathology. The borderline SIDS group includes cases with pre-existing 
congenital disorders, clinical symptoms and/or post mortem findings not sufficient to 
be the cause of death. For the non-SIDS cases the cause of death is established, either 
by clinical information and/or post mortem findings. The term unclassified is not 
used, and thus a few unclassified cases are named borderline SIDS.  
Since 1992 all SIDS cases have been evaluated according to the Nordic criteria at 
the Institute of Forensic Medicine in Oslo. Cases from the period 1984-1992 were re-
classified blindly using the new classification criteria, which lead to change of 
diagnosis in 10% of the cases (58). Cases of sudden unexplained deaths of infants 
from the second week after birth until week 52, were included in the diagnostic. A 
few of the small children who suffered sudden unexpected and unexplained death 
were also included in the diagnostic. They comprise 13% of the total SIDS-population 
and are now classified as sudden death in small children (SUDIC) (56).  
 
1.3 SIDS and infection  
In 1947 Werne et al suggested that respiratory infection was the cause of death in an 
otherwise healthy infant (59). Since then, there has been numerous reports and papers 
describing signs of slight infection in SIDS infants. An immunological “overreaction” 
has been postulated since about half of the SIDS victims have had symptoms of slight 
infection in the days before death (60, 61).  
Arnon et al (1978) have hypothesized that some infants might suffer respiratory 
arrest due to botulinium toxin produced by Clostridium Botulinum (62). From a 
cohort of 280 infants they showed that botulinum toxin was present in 10 infants, of 
which 9 had been diagnosed as SIDS (62).  
  Stoltenberg et al have reported immune stimulation in both the upper airways and 
intestines, showing that SIDS had higher number of IgM immunocytes in the tracheal 
wall than controls, but significantly lower numbers of IgA and IgM immunocytes 
than cases of infectious death (63). In the duodenal mucosa the number of IgA 
immunocytes was higher in SIDS cases than in controls (63). These findings indicate 
that the mucosal immune system is activated in a large proportion of SIDS. It is also 
shown that SIDS have higher IgG and IgA-immunocyte density in the palatin tonsillar 
16 
 
compartments than controls (64). Furthermore, salivary glands have a higher number 
of CD45+ stromal leukocytes, as well as intensified epithelial expression of HLA-DR 
and secretory component, and increased endothelial expression of HLA class I and II 
(65). These observations  confirm that the immune system is activated in SIDS, 
probably with release of certain cytokines that are known to up-regulate epithelial 
expression of HLA-DR and secretory component (65).   
A real  breakthrough for the immunological overreaction theory was the 
demonstration by Vege et al (66), who showed that SIDS victims who have had signs 
of slight infection prior to death had both increased number of  IgA-immunocytes and 
HLA-DR expression in their laryngeal mucosa, as well as increased levels of IL-6 in 
their cerebrospinal fluid (CSF) (Figure 3). In fact, half of the SIDS victims had CSF 
IL-6 concentrations in the same range as victims of meningitis and septicemia (60).  
A further support for the infection theory is a study performed on registry data from 
Norway and Sweden which suggests that there is a co-variation between epidemics of 
whopping cough and SIDS (67). The association was stronger in Sweden than in 
Norway, which may reflect that Swedish infants not are vaccinated against Bordetella 
pertussis while the Norwegians infants are (67).    
   Recently, Stray-Pedersen et al showed that SIDS victims with positive 
Helicobacter pylori Stool Antigen (HpSA) immunoassay had elevated  IL-6 in the 
cerebrospinal fluid compared to SIDS victims with negative HpSA test (68). 
Furthermore, detection of helicobacter pylori antigen in stool was found associated 
with SIDS and death due to infection, indicating that this bacteria may represent a 
contributing factor to sudden death during the first months of life (68).  
   Surfactant protein A (SP-A) is a protein produced in the lungs, with a major 
purpose to reduce the surface tension at the alveolar air-liquid interface. Furthermore, 
it takes part in regulation of the inflammatory process. Interestingly, with regard to 
SIDS there is a drop in alveolar SP-A expression in the first months after birth (69), 
corresponding to the classical age peak of SIDS. Thus it may be hypothesized that 
this transient low expression of SP-A may be a part of the increased vulnerability for 
SIDS at that age (69).   
   It is also suggested that Staphylococcus aureus (S.aureus) are involved in events 
leading up to SIDS (70). Based on observations from samples collected from the 
intestinal tract in SIDS compared with samples from feces from a group of healthy 
controls, it was shown that S. aureus and staphylococcal enterotoxins were more 
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prevalent in SIDS (70). However, as much as 40% of the controls were positive for 
S.Aureus, indicating that this bacteria is common in infants, and that the detection 
may not be seen as a support for the diagnose of SIDS.  
Another study investigated pyrogenic toxins of S.aureus in SIDS infants from 
different countries (71). The study reported these pyrogenic toxins in > 50% of SIDS 
infants from three different countries; Scotland, France and Australia, and suggest 
that further investigation into the effect of the toxins may be important (71).  A study 
by Blackwell et al found that the prevalence of the aureus in nasopharyngeal flora 
was significantly higher in SIDS cases compared to age matched healthy controls 
(72). Furthermore, SIDS found in a prone sleeping position more often had symptoms 
of slight infection prior to death than the babies put to sleep on their back.  
The level of IgA imunocytes in larynx are found to be higher in SIDS victims than 
in control. (66, 73). Furthermore, the relationship between laryngeal immune 
stimulation, clinical signs of slight infection prior to death and high levels of IL-6 in 
CSF (66) may indicate an interaction between the immune system and the central 
nervous system (CNS). The assumption of such a relationship is strengthened by the 
recently reported increased IL-6 receptor expression on serotonergic cells in brain 
stem nuclei involved in respiratory regulation in SIDS cases compared to controls 
(74). The fact that a large proportion of SIDS victims whose brain stems had been 
investigated had had a common cold prior to death, strengthens the hypothesis that 
there may be a connection between activation of the mucosal immune system and a 
dysfunction of the seretonergic network regulating respiration and heart function in 
SIDS.  
  In summary, these studies indicate that a significant proportion of SIDS victims 
have an activated immune system (Figure 3) that seems to  cause autonomic 
dysregulation inducing down-regulation of respiration, irreversible hypoxia and 
death. Scares in the brain stem of SIDS victims indicate either a predisposition 
acquired before birth (75, 76) or they represent sequela after a previously survived 
apparent life threatening event (ALTE) (77). Increased concentration of hypoxanthine 
in vitreous humour and urine of SIDS victims (Figure 3) represent repeated episodes 
of hypoxia shortly before death (19, 20, 76, 78-80). A possible pathogenesis of SIDS 
may be summarized by a vicious circle triggered by environmental factors such as a 
common cold combined with prone sleeping position. An immune reaction out of 
homeostatic control induces serotonergic imbalance which consequently leads to 
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impaired breathing, hypoxia and death (73, 81). The purpose of this thesis is to search 
for genetic factors that may explain the fatal disturbances of this immunological 
homeostasis.     
 
  
 
Figure 3: The salivary glands, tonsils, laryngeal and duodenal mucosa show 
increased number of immune producing cells compared to controls (63-65). The 
number of IgA-immunocytes and HLA-DR expression are increased in laryngeal 
mucosa, and the CSF show elevated IL-6 concentration (66). Vitreous humour and 
urine contain increased amount of  hypoxanthine due to ante mortem hypoxia (20, 78, 
80) 
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1.4 Cytokines  
The discovery of cytokines was initiated by research trying to understand the 
pathogenesis of fever. Cytokines are specialized peptides, proteins, and glycoproteins 
that are produced by different immune cells, for instance when exposed to a pathogen. 
Important functions of the cytokines are to supervise cell communication and regulate 
the cells activity during the inflammatory process, making the cytokines important 
intercellular mediators. The different cytokines and their system of mutual interaction 
are known as the cytokine network, and until now at least 36 different human 
cytokines have been detected. The cytokines may be subdivided into different groups 
of proteins, and most important are the interleukins (IL), the tumor necrosis factors 
(TNF) and the interferons (IFN), which all are highly involved in the immunological 
process during an infection. The cytokines can act in a paracrine and autocrine 
manner, and are commonly divided into pro-inflammatory and anti-inflammatory 
cytokines.   
Interleukins are signaling molecules that were first discovered as products of 
leukocytes, but they are also produced by other immune cells such as monocytes, 
macrophages and endothelial cells. Several interleukins have been described, and they 
all have a specific involvement in the immunological process.  
 
1.5 Pro-inflammatory cytokines  
The pro-inflammatory cytokines are immunoregulators that favor inflammation. The 
most important are IL-1α, IL-1β, IL-6, IL-8, IL-12, IL-18, TNFα and IFNγ. These 
cytokines act as endogenous pyrogenes (IL-1, IL-6, TNFα), up-regulate the synthesis 
of secondary mediators and other pro-inflammatory cytokines produced by both 
macrophages and mesenchymal cells (including fibroblast, epithelial and endothelial 
cells), stimulate the production of acute phase proteins, and attract inflammatory 
cells. 
  
1.5.1 Interleukin 1α 
Interleukin 1α (IL-1α) is an epidermal cytokine produced continuously by monocytes, 
tissue macrophages, keratinocytes and other epithelial cells. IL-1α is found in large 
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concentrations in the epidermis, which is due to the essential role of IL-1α preventing 
entry of microorganisms through the skin, and helping the lymphocytes to fight 
infection. IL-1α is also responsible for the migration of leukocytes through the blood 
vessels, and causes fever by affecting the thermo-regulating area of the brain. The 
protein is quite large, and it is stored in the cells until it is cleaved into a mature 
version of the protein. The gene encoding IL-1α is located on the long arm of 
chromosome 2 (cytogenetic location 2q14). The most commonly investigated genetic 
variations in the IL-1α gene are the SNPs in base pair +4845 and +889 relative to 
upstream transcription start. The IL-1α +889 polymorphism have been shown to alter 
the production of IL-1α (82), while the polymorphism in +4845 is thought to affect 
the sensibility to calpains, and the ability to cleave the pro-protein into the active form 
(83). It has been shown that the +4845T allele occur more frequent in patients with 
chronic polyarthritis, and also that +4845 is associated with polymyalgia rheumatica 
(84, 85).  A VNTR in intron 6 of the gene has also been reported, and even though it 
has not been reported any simple clear-cut correlation between IL-1α production and 
number of repeats it has been suggested that IL-1α production decreases with 
increasing number of the intronic repeat sequence (86).   
 
1.5.2 Interleukin 1β 
Interleukin 1β (IL-1β) is produced as a pro-protein by monocytes, activated 
macrophages and dendritic cells, and it is an important mediator in a variety of 
cellular responses in the immune-activated cell. The most important roles of the IL-1β 
are cell proliferation, differentiation, and apoptosis. Even just a small amount of  
IL-1β will induce fever and hypotension, and stimulate the production of other 
cytokines. Two polymorphisms of particular interest within the gene have been 
reported, the SNPs -511C/T and +2018T/C. Regarding -511C/T it is shown that the T 
allele will induce increased production of IL-1β, while the C allele might influence 
the production in the opposite direction (87). The IL-1β-511T allele has been reported 
to be less frequent in patients with Helicobacter pylori infection in early onset 
immune thrombocytopenic purpura (ITP) (88) .  
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1.5.3 Interleukin 6 
Interleukin-6 (IL-6) is a protein produced by T-cells, macrophages, and endothelial 
cells.  Its major function is as an acute phase protein, where it stimulates B- and T- 
cell growth and differentiation. IL-6 is also an important mediator of fever, and the 
protein can influence the effect of other cytokines. IL-6 can function both as a pro- 
and anti-inflammatory cytokine. As an anti-inflammatory cytokine it is inhibiting 
TNFα and IL-1 production, and triggering IL-1ra and IL-10 activation. The gene is 
located on chromosome 7, at position 7p21, and several polymorphisms have been 
reported. The most frequent studied genetic variation is a SNP located in the promoter 
region of the gene, -174G/C. Several studies have shown that this SNP regulate the 
production of the protein, and that the -174G allele seems to be associated with high 
levels of IL-6 (89, 90). The wild type allele in position -597 and -174 have been 
found associated with an unfavorable outcome of chronic hepatitis C virus (HCV) 
infection, in particularly in males (91).    
 
1.5.4 TNFα 
Tumor necrosis factor alpha (TNFα) is a transmembrane protein produced by 
macrophages, monocytes, neutrophils, T-cells and NK-cells as a result of the presence 
of bacterial toxins. Its primary function is to regulate immune cells, induce apoptotic 
cell death, stimulate inflammation, and control viral replication.  The gene encoding 
TNFα is located on chromosome 6, position 6p21.3, which is a very polymorphic 
region of the chromosome with a cluster of immune genes, including the major 
histocompability complex (MCH) and complement component C4. The TNFα gene 
also contains a large number of polymorphisms, including -1031T/C, -857C/T,  
-244G/A, -308A/G and -238G/A. The -308 allele is the most studied variant, and this 
SNP has been found associated with a number of diseases such as rheumatic heart 
disease and obstructive sleep apnea syndrome (92, 93). The -308A allele is also 
reported associated with severe cerebral malaria, and with death due to 
meningococcal sepsis and septic shock (94-96).  
 
1.5.5 Interleukin 8 
Interleukin 8 (IL-8) is a chemokine produced mainly by macrophages and epithelial 
cells, but also by the endothelial cells were it is stored in vesicles.  The main function 
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is to serve as a chemical signal that recruit neutrophils and induce chemotaxis in 
target cells, which causes the migration of neutrophil cells from the blood stream to 
the tissue.  The gene encoding IL-8 is on chromosome 4, position 4q12-q21, and 
several SNPs have been reported. The most investigated SNP is -251A/T, and 
association between the -251AA and high IL-8 production have been reported in 
patients with diarrhea (97).  Hull et al showed an association between the -251A allele 
and vulnerability to disease after a respiratory syncytial virus (RSV) infection (98), 
and in a Japanese study an association between -251A and gastric ulcer and gastric 
cancer in patients with Helicobacter pylori infection was found (99).  
  
1.5.6 Interleukin 12 
Interleukin 12 (IL-12) is produced by dendritic cells and phagocytes, and is a T-cell 
stimulating factor responsible for differentiation of T-cells. IL-12 also activates IFN-γ 
and TNFα production.  IL-12 is able to block the formation of new blood vessels. 
This anti-angiogenic activity is achieved by stimulating the production of IFN-γ 
which in turn mediate the release of a chemokine. The two chains forming the IL-12 
complex are coded by the two genes IL-12A and IL-12B, which is located at 3p12-
13.2 and 5q31.1-q33.1 respectively. Several polymorphisms have been described that 
have functional effect in both subunits (100, 101). A study performed on multiple 
sclerosis patients suggests that IL-12 +1188A/C together with a SNP in interferon 
gamma at position +874A/T could be a risk factor for developing the disease (102).  
 
1.5.7 Interleukin 18  
Interleukin 18 (IL-18) is produced by macrophages, and induces cell mediated 
immunity as a response to bacterial toxins, as well as stimulates the production of 
IFN-γ. The gene is located on chromosome 11, and mapped to position 11q22.2-
q22.3. Several SNPs have been reported, including -607C/A and -137G/C. These 
SNPs have been found associated with increased risk of ischemic stroke (103). 
Another study found that the -607C allele was associated with systemic lupus 
erythematosus, and that the C allele may result in an enhanced production of IL-18 
(104).  
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1.5.8 IFN-γ 
Interferon gamma (IFN-γ) is produced by natural killer cells (NK cells), and by CD4 
and CD8 cytotoxic T lymphocytes. It is an important cytokine for the immunological 
resistance against viral and bacterial infection as well as for tumor control. However, 
it’ most important effects are attributable to its immunostimulatory and 
immunomodulatory effects. The gene encoding IFN-γ is located on chromosome 12, 
position 12q15. Several SNPs have been reported in this gene, the most commonly 
investigated are -764G/C, +874A/C  and -179T/G. It has been demonstrated an 
association between IFNγ +874A and severe acute respiratory syndrome, and it is 
suggested that the allele might be involved in the pathogenesis of severe acute 
respiratory syndrome (SARS) due its ability to alter the IFN-γ production. (105).  The 
+874AA genotype have been found associated with hepatitis B (106), while the 
+874T allele is associated with symptomatic parvovirus B19 infection (107).    
 
1.6 Anti-inflammatory cytokines  
Anti-inflammatory cytokines are immunoregulatory cytokines that control the pro-
inflammatory cytokines by reducing their production, and thus counteract their 
biological effect. The major anti-inflammatory cytokines are interleukin 1 receptor 
antagonist (IL-1ra), IL-4, IL-10, IL-11, and IL-13.  
 
1.6.1 Interleukin 13 
Interleukin 13 (IL-13) is a protein secreted by activated T lymphocytes, and IL-13 
controls the functions of monocytes and B-cells. It has structural similarities with  
IL-4, and thus has similar functional effects and a common signaling pathway. One 
important role for IL-13 is to down-regulate the production of TNFα. The gene 
encoding for IL-13 is located in a cluster of other interleukin genes at chromosome 5, 
and maps to position 5q23. This gene is not as polymorph as many other interleukin 
genes, but some SNPs have been reported, including the haplotype variant  
-1112T/+2044A that have been shown to be decreased in patients with Graves’ 
disease (108). Also a regulating SNP at position  +4464A/G (glu110arg), has been 
reported, and the 110arg allele is reported associated with asthma (109).   
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1.6.2 Interleukin 16 
Interleukin 16 (IL-16) is in general produced by lymphocytes and epithelial cells, and 
works as a chemo-attractant for CD4+ cells, monocytes and eosionphils. IL-16 can 
also stimulate the production of IL-2 receptors and induce HLA-DR expression. The 
gene encoding IL-16 is located at chromosome 15, position 15q26.1. The most 
common SNP is -295T/C, and it is demonstrated that the -295T allele induces a 
reduced promoter activity in patients with asthma (110).  It has also been shown an 
association between specific variants of three SNPs, including the G allele of 
rs11556218, -285C and the T allele of rs4072111, and increased risk of systemic 
lupus erythematosus (111).  
  
1.6.3 Interleukin 1ra 
Interleukin l receptor antagonist (IL-1ra) is a protein which inhibits IL-1α and IL-1β 
by blocking the IL-1 receptors, resulting in lack of biological effects for these 
interleukins. IL-1ra is produced by macrophages and monocytes, and released in a 
much higher concentration than both IL-1α and IL-1β. The gene encoding IL-1ra is 
mapped to 2q13-q14.1. The most commonly investigated polymorphism in the IL-1ra 
gene is a VNTR in intron 2 of the gene, and it is shown that the IL-1ra allele 2 is more 
frequent in patients with chronic inflammatory disease as well as in autoimmune 
disease and solid tumors (112).  
 
1.7 Genetic variations 
1.7.1 Mutations 
A mutation is defined as an alteration in genetic material. A point mutation is defined 
as the replacement of one base in DNA with another, which may have different 
outcome, depending on the location in the gene.  
A missense mutation results in a change in the codon, and thereby to the 
introduction of a new amino acid in a given protein. A well known example of this is 
sickle cell anemia that is caused by an autosomal recessive mutation in the β-globulin 
gene, where an adenine (A) to thymin (T) change make an alteration in the codon 
from GAG to GTG, and further to an amino acid alteration, where the hydrophobic 
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amino acid valine replaces the hydrophilic glutamic acid at the sixth amino acid 
position of the polypeptide chain.  
A nonsense mutation is a point mutation that changes the codon into a stop codon, 
resulting in a truncated protein with suboptimal function, while a silent mutation is a 
change that does not alter the codon, and thus does not affect the protein. An insertion 
or deletion mutation adds or removes segments of DNA. Such changes may include 
only a few base pairs, or may be more extensive losses or gain of DNA. Transposons 
are mobile genetic elements that can also cause mutations.  
Most genetic mutations are harmful for the organism. Therefore, the cells have 
repair mechanisms in order to avoid accumulation of defected proteins.   
 
1.7.2 Polymorphisms 
Polymorphisms are genetic variations inherited along Mendelian lines in a family that 
by definition should occur at a frequency of 1% or more within a population. In 
genetics, polymorphisms describes the diversity within a population. Translated it 
means “many forms”, and polymorphisms that are conserved through generations are 
the evolutionary strongest genetic markers. A polymorphism may or may not have a 
biological effect. Single nucleotide polymorphisms (SNP) are variations in a single 
nucleotide at a given position in the genome. SNPs are very common, and can be 
observed at every 100 to 300 base along the human genome, which consists of 
approximately 3 billion bases. The most common variation is the replacement of 
thymine (T) with cytosine (C). SNPs can occur anywhere along the DNA strand, and 
might affect the coding or the non-coding part of a gene. Due to the stability and 
ability to conserve SNPs in generations, such genetic variation is an important tool for 
population studies.   
Most SNPs have no functional effect on biological processes, even if they are 
located within the coding sequence of a gene. However, some of the SNPs might 
affect the synthesis of the given protein, and thus predispose to disease. It is important 
to bear in mind that a SNP does not cause disease by itself, but may be used as a 
marker for the probability that someone will develop a disease. An example of SNPs 
as markers for disease is the different allele types for apolipoprotein E (ApoE), were 
the allele E4 has shown to be found more often in patient that develops Alzheimer 
disease (113).  
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Copy number variations (CNV) are duplications or deletions of large segments of 
DNA, and approximately 2000 CNVs have been described in the human genome. The 
size of the duplicated or deleted sequence may vary from about approximately one 
thousand base pairs to an entire gene. CNVs that effect critical developmental genes 
may cause disease.  
Various number of tandem repeats (VNTR) are nucleotide sequences that is 
repeated one after another tandemly (Figure 4). The repeated sequence may vary in 
length, from only a few bases to hundred or more, and the number of repeats at a 
given position may vary between individuals.  A VNTR may influence the expression 
of a gene, leading to a higher or lower protein level. As for SNPs, VNTRs cannot 
cause disease by themselves, but may be used as markers for the risk of developing 
certain diseases. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Illustrating four types of genetic variations; deletion, insertion, CNV and 
VNTR.   
      Reference    Deletion    Insertion    Copy number    
      genes                                               variation (CNV) 
Various number of tandem 
repeats (VNTR) 
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2 Previous studies on SIDS and polymorphisms in genes 
involved in the immune system 
The first gene involved in the immune system to be investigated with regard to SIDS 
was the gene encoding complement component C4. The C4 gene was investigated in 
40 German and 104 Norwegian SIDS victims, and both studies found an association 
between slight infection prior to death and partial deletions of the C4 gene, indicating 
that this combination of genetic make-up and environmental influence, may increase 
the risk for SIDS (51, 52). 
The candidate genes most likely to explain the vulnerability to infection are the 
cytokine genes. Several studies have investigated these genes in an attempt to uncover 
associations between SIDS and different genetic variants (114-119). IL-10 is an 
important immune regulatory cytokine, and the SNPs in the promoter region in 
position -1082, -819 and -592, as well as the microsatellite IL-10R and IL-10G, are 
collectively responsible for the production of the protein (120). Both SIDS cases and 
cases of infectious death have been reported associated with the ATA haplotype and 
the ATA/ATA genotype of this gene (114, 115). In addition, a higher percentage of 
the genotypes G21/G22 and G21/G23 in cases of infectious death compared to SIDS, 
and a higher percentage of G21/G22 in the SIDS cases compared to controls have 
been reported (114). Based on these findings it may be speculated that in some 
situations an infant with an unfavorable IL-10 genotype may exhibit aberrant IL-10 
production, which in turn leads to a disturbed immunological homeostasis.   
The polymorphisms IL-1β -511C/T and +2018T/C, located in the IL-1Ra gene, 
have a significant effect on the IL-1β levels, but no association to SIDS has so far 
been established (116). Another study investigated the 89bp VNTR in the IL-1Ra 
gene in Australian SIDS cases, and found that carriage of the 2/2 genotype increased 
the risk for SIDS compared with the predominant 1/1 genotype (121). Homozygous 
carriers of allele 2 show a more severe and also prolonged proinflammatory immune 
response compared to other IL-1Ra genotypes (112), which may contribute to the 
vulnerability to infection seen in SIDS.  
A British study including common polymorphisms in the genes encoding IL-4, 
IL-6, IFN-, TGF, and VEGF found significant differences for the genes encoding  
IL-6 and VEGF: the genotypes -174GG, and -1154AA were more frequent in SIDS 
cases than in controls (117). Even though only a small number of SIDS cases was 
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included, the authors suggest that the causation of SIDS is related to both fetal lung 
development and an infant`s innate ability to mount an inflammatory response to 
infection (117). The findings regarding the IL-6 gene has been confirmed in a study 
of Australian SIDS cases (118), but not in a Norwegian study (119).  
Surfactant protein A (SP-A) and surfactant protein D (SP-D) are humoral 
molecules involved in the innate host defense against various bacterial and viral 
pathogens. Ten SNPs that might influence expression of the genes encoding these two 
surfactants have been investigated in SIDS cases and controls (122). No difference in 
genotype distribution was found, even though there was a tendency for the most 
common SP-A haplotype, 6A2/1A0, to be overrepresented in cases with low 
immunohistochemical SP-A expression (122). The SP-D expression was not 
influenced by any of the investigated SNPs.  
An increased vulnerability to infection may also be due to genetic variation in the 
genes encoding G-proteins. The most investigated polymorphism in the Gβ3 gene is 
C825T, and it is shown that T-allele results in increased G protein mediated signal 
transduction compared to the C-allele (123). Most interleukin-receptors are G-protein 
coupled, and an association between the Gβ3 825T allele and increased cell function 
has been reported. A study of the C825T polymorphism in SIDS victims, cases of 
infectious death and live infant controls, revealed no difference in genotype frequency 
between SIDS cases and controls (124), but an association between the CC genotype 
and infectious death was found. The observation may indicate that the presence of the 
825T allele exerts a protective effect towards serious infection, perhaps through 
enhanced G protein signaling (124). 
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3 Aims of the study 
The main hypothesis of this thesis is that infants that die from SIDS, besides being at 
a vulnerable developmental stage, have a combination of polymorphisms in genes 
involved in the immune system, that predispose to disturbed homeostasis when 
challenged by virus or bacterial infection. Most important for such a mechanism 
seems to be the genes encoding the interleukins. Based on this assumption the 
following objectives were formulated:  
 
1. To search for genetic predisposing factors in the gene encoding TNFα in SIDS 
victims and infants suffering infectious death. A SNP profile will be created with the 
given genotype combination of all SNPs. The aim was to disclose whether 
polymorphisms expressed in certain genotype combinations were associated with 
SIDS and infectious deaths, because possible significant associations might be 
camouflaged in a single SNP study.  
 
2. To investigate functional polymorphisms in the cytokine network in a case-control 
study of SIDS victims, infectious deaths and adult controls. The SNPs and VNTR to 
be included should be selected due to their previously reported functional effect. 
Because all the cytokines function together in a well regulated network it would also 
be of interest to construct a SNP profile, to further understand the total effect. Based 
on the concept of the fatal triangle for SIDS (76) we also wanted to examine possible 
associations between specific interleukin genotypes and environmental risk factors for 
SIDS, including prone sleeping position, co-sleeping, maternal smoking, and slight 
infection.  
 
3.  To search for a possible association between interleukin gene polymorphisms, slight 
infection, and immunstimulation of the laryngeal mucosa in SIDS. By using HLA-DR 
expression in laryngeal mucosa as a marker of immune stimulation, the SIDS victims 
were classified with regard to degree of immune stimulation. To search for possible 
genetic risk factors for SIDS we wanted to study the genetic makeup in the 
interleukin genes in SIDS victims with intense and extended laryngeal HLA-DR 
expression compared to SIDS cases that did not show signs of such expression.    
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4 Material and methods  
4.1 Subjects  
The subjects included in the studies of this thesis were all examined at the Institute of 
Forensic Medicine, University of Oslo, during the period 1988-2006. The autopsies 
were performed as soon as possible after death and for most cases within 36 hours. 
Tissue samples and body fluids were collected in all cases based on a well established 
protocol (26, 125-127), and the post mortem examinations of every infant was 
performed by the same forensic pathologists (TOR, ÅV, MA, ASP). All individuals 
were Caucasians from the south-eastern part of Norway.  
The subjects included 148 SIDS cases, 56 borderline SIDS cases, 41 cases of 
infectious death, and 131 adult diseased controls (table 2). The SIDS and borderline 
SIDS cases were diagnosed according to the Nordic criteria (26), were it is demanded 
that both clinical history, autopsy findings and investigation of the circumstances of 
death provides no explanation of death. The cases undergo a full body X-ray prior to 
autopsy, and before a diagnosis of SIDS or borderline SIDS can be established, 
toxicological screening has to be negative, and mutations and functional 
polymorphisms in the LQTS genes, as well as the A985G mutation in the MCAD 
gene, have to be excluded. Afterwards, an informed consent questionnaire was send 
to the SIDS parents to obtain knowledge of the history of the child’s health in the 
days before death, parental smoking, position when found dead and sleeping 
environment. All subjects included in the group of infectious death died suddenly and 
unexpectedly, without a history of severe illness prior to death. The causes of death in 
the control group were acute non-infectious disease, trauma, and intoxication.  
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Table 2: Survey of the patients  
Group   Number 
of cases  
Diagnosis      Gender      
            (F/M) 
Age at time of death, 
median (range) 
SIDS 148 SIDS 57/91 3.8 mo (0.1-24 mo) 
 56 Borderline SIDS 20/36 3.5 mo (0.5-39 mo) 
Infectious death  41 19 pneumonia 13/28 7.6 mo (0.8-39 mo) 
  16 septicaemia   
  1 meningitis    
  2 CMV infection   
  1 encephalitis   
  1 myocarditis    
  1 peritonitis   
     
Controls    131 52 disease 
23 intoxication  
56 violent death 
43/88 49 y (11-86 yrs ) 
     
     
 
4.2 Bioinformatics 
In the papers included in this thesis, a total of 14 SNPs were investigated using 
MassArray technology. As a first step, the genetic variation in the sequences 
surrounding each SNP has to be identified. The surrounding sequence may be 
obtained from the SNP-database, dbSNP, at NCBI 
(http://www.ncbi.nlm.nih.gov/projects/SNP/). In order to use this database the 
reference SNP (rs) or the submitted SNP (ss) number for the SNP has to be known.  
A typical input file should contain about 250 bases up- and down-stream from the 
SNP of interest, and the next step is to localize and mark all genetic variations in this 
approximately 500 bp sequence. This can be done by SNP Basic Local Alignment 
Search Tool, or SNP-BLAST, at UCSC Genome Browser website 
(http://www.genome.ucsc.edu/). At this web site the DNA sequence may also be 
extended, if that obtained from dSNP is not sufficient. This may happen if the 
sequence obtained from the dbSNP is short, or if  the sequence is very polymorphic, 
making it difficult to design primers.  
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In cases were the rs or ss number was not known, the DNA strand was obtained 
from the UCSC Genome Browser by first obtaining knowledge about the primers 
previously used to genotype the SNP, then blasting the reverse and forward primers. 
This will provide the DNA sequence including the SNP of interest. However, the 
product obtained from this procedure will most often not be sufficient to obtain all the 
information necessary to do a multiplex priming. Therefore it may be necessary to 
perform a new blast to obtain a prolonged sequence on both sides.  
When both the SNP of interest, as well as other SNPs in the surrounding 
sequence, have been marked, the sequence have to be repeatmasked. RepeatMasker is 
a program that screens DNA sequences for interspersed repeats and low complexity 
DNA sequences. Approximately half of the human genomic DNA will be masked 
using the repeatmask programs.  These programs are useful for analytical purposes 
using sensitive technology in which interspersed repeats must be known. Several 
programs are available for this task, and the most conservative repeat masking web 
site is the SNPmasker 1 (http://bioinfo.ut.ee/snpmasker/). The one used for most of 
the SNPs in the papers included in this thesis, is the program found at the website  
http://www.repeatmasker.org/cgi-bin/WEBRepeatMasker.  
 
4.3 DNA extraction 
DNA was extracted from spleen using standard methods for robot extraction and the 
BioRobot EZ1 (Qiagene, qiAmp DNA minikit). The robot extractor uses magnetic 
particles technology, where DNA binds to the silica surface of the magnetic particles. 
All reagents are supplied in a kit and are prefilled into cartridges, which ensure a 
sterile environment for the extraction process. The EZ1 provides very pure DNA, 
which is important since only a small amount of DNA are used in the further 
analytical process.  DNA from some of the oldest cases was extracted from blood or 
spleen either in a 340A Nucleic Extractor (Applied Biosystem, Rotterdam, 
Nederland) or manually, both using standard methods (phenol-chloroform extraction 
and ethanol precipitation) (128).  Though the phenol-chloroform and ethanol 
precipitation does yield a higher DNA concentration, the process is time consuming 
and it requires a lot of on-hand laboratory work. The purity of the DNA is not as good 
as the DNA obtained from the BioRobot EZ1.    
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4.4 DNA quantification  
The samples were quantified using realtime PCR (qPCR) and a real time PCR 
machine Mx3000p (Stratagene). The quantification kit used for the analysis was 
Quantifiler (Applied Biosystems). 
When quantifying DNA using a qPCR quantification method, the target 
concentration is calculated as a function of PCR cycle number. The chemistry used 
involves, like conventional PCR, dNTP, primers and polymerase, and the increase of  
amplified products are measured as an accumulation of fluorescence after each PCR 
cycle. The concentration of DNA in the sample is inversely proportional to the cycle 
threshold (ct value), which is the number of cycles needed for the measured 
fluorescent signal to pass the background noise and exceed the threshold. The 
threshold is set to the exponential phase were the reading would be most accurate. A 
real time reading is commonly plotted into a diagram, and the curve will most often 
have a sigmodial shape (figure 5) with the copy number on the Y-axis and the cycle 
number on the X-axis. In the exponential phase the number of DNA strands double 
for every cycle, and a plateau phase is reached when there is no more available 
primers in the mastermix. After quantification, all samples were diluted to a 
concentration of  20 ng/µl.  
 
 
Figure 5: Real-time PCR image with a steady exponential phase for the sample.   
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4.5 Sequenom® multiplex 
The SNPs included in table 3 and figure 6 were genotyped using MassARRAY™ on 
a SEQUENOM® platform, in cooperation with CIGENE, Norwegian University of 
Life science, Ås. As core facility under the Norwegian Functional Genomics program 
(FUGE), CIGENE is a national platform for SNP analysis. The total process is 
automated using highly specialized instruments such as Beckman Biomek Fx 
pipetting robot (Beckman Coulter), a Beckman Multimek96 pipetting robot 
(Beckman Coulter), a nano-dispenser chip-printing robot, a mass spectrometer, and a 
Laboratory Information Management System (LIMS system).  
A multiplex assay was designed using Assay designer software 2.0 
(SEQUENOM® Europe) that automatically design primers. Following polymerase 
chain reaction (PCR) and Shrimp Alkaline Phosphatase (SAP) treatment, a primer 
extension reaction was performed to introduce mass-differences between alleles and 
product, the reaction was further desalted using resin. The PCR product was 
thereafter dispensed onto a SpectroCHIP with 384 patches. Approximately 25nl 
amplicon was transferred onto the pins in the silica chip. The mass difference were 
detected using a matrix assisted laser desorption time-of-flight mass spectrometry 
(MALDI-TOF) and genotypes were called using type 3.1 software (SEQUENOM®). 
The energy from the laser is absorbed by the matrix, which is an important step that 
will cause part of the illuminated substrate to vaporize. Once the laser beam have 
caused vaporization and ionization of the molecules, it is transpired electrostaticly 
into the vacuum tube were the mass-to-charge (m/z) is detected. The time flight for 
the ion in the tube is proportional to the square root of its m/z. Cluster plots were 
made due to the signals of different allele mass. In order to avoid contamination the 
pre- and post-PCR procedures were kept geographically separated, and the sample 
plates had a one way work flow. The gene sequences were obtained from SNP 
database build 127 (http://www.ncbi.nlm.nih.gov/sites/entrez) 
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Table 3: Functional SNPs investigated using MassArray 
    
Gene Polymorphism rs number 
IL-1α +4845G/T rs17561  
IL-1β -511C/T rs16944  
IL-6 -572G/C  rs1800796 
IL-8 -781C/T  
-251A/T  
rs2227306 
rs4073 
IL-12 +1188A/C rs3212227 
IL-13 +4464 A/G rs20541 
IL-16 -295T/C rs4778889 
IL-18 -137G/C rs187238 
TNF-α -1031C/T 
-857 T/C  
-244A/G,   
-238 A/G 
rs1799964  
rs2507961 
rs673  
rs361525  
IFN-γ +874A/T rs2430561 
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Figure 6: Chromosomal localization of the polymorphisms studied in the present thesis.   
IFN-γ 
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4.6 TaqMan genotyping 
One of the SNPs in the TNFα gene, -1031C/T, was analyzed using TaqMan SNP 
genotyping assay (Applied Biosystems) and Mx3000p real-time PCR machine 
(Stratagene, a Jolla, CA). The assay id was C_7514871_10. The TaqMan genotyping 
assay is based on allelic discrimination using two allele-specific fluorescent probes 
together with primers flanking the sequence of the SNP. The probes have a quencher 
at the 3’ end to avoid fluorescence signal. The two probes are marked with different 
reporter fluorescence at the 5’ end, both specific to one of the alleles. When the target 
specific probe anneal to the sequence, the quencher is released from the probe and the 
fluorescence can be measured (Figure 7).   
 
 
 
 
 
 
 
 
 
Figure 7: Allelic discrimination by TaqMan probes. The probes are labeled with the 
fluorophore VIC or FAM. These are attached to the probes, and the quencher prevents  
liberation of the reporter fluorescence if the probe is not degraded. The Minor Groove 
Binder (MGB) function as a stabilizer for the double-stranded structure formed between 
the target and the probe. Probes that hybridize specifically to DNA fragments are 
destroyed and the fluorescence of corresponding fluorophore is liberated and creating a 
signal. (Source Applied Biosystems).  
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4.7 Sequencing 
DNA sequencing is an analytical method that determines the exact nucleotide 
(adenin, thymin, cytocine and guanine) order in a given DNA strand. One sequencing 
method is the dideoxy metode that synthesizes DNA from four deoxynucleotide 
triphosphates (dTTP). This is achieved by adding a new nucleotide to the 3’ –OH 
group at the growing DNA strand. The elongating is terminated when there is no  
3’ –OH group attached to the last nucleotide. The reaction mixture contains all four 
normal nucleotides (dNTP) and the dideoxynucleotides (ddNTP), the latter in limited 
concentration. All are labeled with a different fluorescence color. When the 
elongation have been terminated, the fragments are separated based on their length, 
and the fluorescence from the different dideoxynucleotides are visualized by laser.         
 
4.8 Construction of SNP profiles and VNTR/SNP combinations 
In paper I, a TNFα SNP profile was made for 135 of the SIDS cases,  56 of the 
borderline SIDS cases, 38 of the cases of infectious death and 126 controls. This was 
done by assigning the genotypes of every SNP with a number from 1-3, were the 
most common homozygote was 1, heterozygote 2, and homozygote for the other 
allele 3. The genotype combinations for all cases were plotted manually. Only the 
cases with results in all SNPs were included. The SNP -244 was excluded from the 
profile construction as it was found to be heterogeneous in the population.   
In paper II, a SNP profile was constructed for the pro- (IL-6, IL-8, IL-12, IL-18 
and IFN-γ) and anti- inflammatory interleukins (IL-13 and IL-16) separately, and also 
for interleukins located on the same chromosome. This was performed by clustering 
the SNPs belonging to the appropriate group.  
In paper III, a combined SNP/VNTR gene combination was constructed in 135 
SIDS cases, 56 borderline SIDS cases, 38 cases of infectious death and 126 controls.  
 
4.9 Allele specific PCR 
The TNFα-308G/A (rs1800629) polymorphism was genotyped using allele specific 
PCR. The PCR reaction was performed using standard protocols for normal 
amplification. Each sample was included in two PCR reactions with different 
sequence specific primers, the primer pairs used together were TNF-α1 / TNF-α2 and 
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TNF-α1 / TNF-α3 (table 4). In addition, the PCR reactions included internal control 
primers, IK1 and IK2, to avoid false negative results (129). The PCR conditions were 
95 oC for 30s, 64 oC for 30s, and 72 oC for 30s, 30 cycles (129).   
 
Table 4: Primer sequences for allele specific genotyping of TNFα -308 A/G.  
 
Area Primer Sequence  
-308G TNF-α1: 5’-CTCGGTTTCTTCTCCATCG-3’,  
TNF-α2: 5’-ATAGGTTTTGAGGGGCATGG-3’,  
-308A TNF-α1: 5’-CTCGGTTTCTTCTCCATCG-3’ 
TNF α3: 5’-AATAGGTTTTGAGGGGCATGA-3’ 
Human 
Growth 
Hormone 
IK1, 5'-GCCTTCCCAACCATTCCCTTA-3' 
IK2, 5'-TCACGGATTTCTGTTGTGTTTC-3'  
 
4.10 VNTR analyses 
Two VNTRs were analyzed in the papers included in this thesis, a VNTR in intron 2 
of the IL-1ra gene and a VNTR in intron 6 of the IL-1α gene. The polymerase chain 
reaction was performed using standard protocols for normal amplification. Primers 
for both VNTRs were designed using the program Primer3 (http://frodo.wi.mit.edu). 
The sequences of the primers flanking the IL-1α VNTR were  
5’-GCCTCTAGACTCATAGAACTTAGTC-3’, and  
5’-GTGAGGTCAGGCCATTGCACTG-3’. The temperature profile was 96 oC for 1 
min, 58 oC for 1 min, and 74 oC for 6 min, for 30 cycles, followed by a final extension 
at 72 oC for 10 min. The sequences of the primers flanking the IL-1ra VNTR were  
5’-CTCAGCAACACTCCTAT-3’ and 5’-TCCTGGTCTGCAGGTAA-3’. The 
temperature profile was 95◦C for 30 sec, 60◦C for 30 sec, 72◦C for 30 sec, for 30 
cycles, followed by a 10 min final extension at 72◦C.  
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4.11 Gel electrophoresis  
Amplified products were detected by gel electrophoresis on 2% agarose gels in the 
presence of ethidium bromide, and the DNA bands were visualized using ultra violet 
(UV) light. The PCR products of TNFα were 185 bp of size, the IK product were  
427 bp. The alleles of the VNTR in intron 6 of the IL-1α gene ranged from 620 bp to 
1220 bp, while the alleles of the VNTR in intron 2 of the IL-1ra gene ranged from 
240 bp to 595 bp.   
 
4.12 Immunohistochemistry, HLA-DR  
Tissue sections from laryngeal mucosa were stained using immunohistochemistry. 
The primary antibody used was a mouse anti-human HLA-DR monoclonal antibody 
which were incubated with components of the Envision detection system 
peroxidase/DAB+ labeled rabbit anti mouse (EnVision+/HRP/Mo, Dako, Glostrup, 
Denmark). Negative controls were treated identically, except that the primary 
antibodies were omitted. 
To evaluate the HLD-DR expression in mucosal glands and surface epithelium  
scores were given according to a previously reported protocol, with slight 
modification (66). Four variables were evaluated in each tissue section: staining 
intensity and extensiveness of positive staining of both surface epithelium and 
mucosal glands. Intense positive staining in surface epithelium (squamous and 
columnar) and glands was given a score of 2, intermediate staining was scored  1, and 
no staining in the surface epithelium and glands was scored 0. As to the extensiveness 
of staining, more than 50% of the cells was scored 2, staining up to 50% of the cells 
was scored 1, and no staining was scored 0. The slides were evaluated using a 
LeicaDMLB microscope (Leica Microscopie and system GmbH, Wetzlar, Germany) 
equipped with 10x magnification of the ocular lens and 40x magnification of the 
objective. Images of the slides were taken with a Leica digital camera.    
Blind inter – and intra observer reproducibility testing of the scoring of intensity 
and extensiveness of staining was performed involving two observers (LF, ÅV). 
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4.13 Statistical analyses 
The χ2 – test was used for comparing the frequencies of the different polymorphisms 
between the diagnostic groups, as well as to correlate genotypes with external risk 
factors for SIDS. When cell count was low (<5), the Monte Carlo test was applied. 
For testing of inter- and intra-observer reproducibility regarding scoring of HLA-DR 
expression, the Kappa test was performed. The level of significance was set to 0.05. 
When investigating the relationship between interleukin levels in the CSF and HLA-
DR expression, the Kruskal-Wallis test was used. Calculations for paper I was 
performed using SPSS version 14.0, for the other papers SPSS version 16.0 was used 
(SPSS, Chicago, IL, USA). 
Hardy Weinberg equilibrium was calculated using OEGE - Online Encyclopedia 
for Genetic Epidemiology studies. 
4.14 Registry and approval  
All the studies were approved by the Committee for Medical Research Ethics in 
Southern Norway (REK sør, ref nr S-06264a).   
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5 Summary of papers  
5.1 Paper I 
Ferrante L, Opdal SH, Vege Å, Rognum TO. TNF-α promoter polymorphisms in 
sudden infant death. Hum Immunol 2008;69:368-73.  
Several studies have suggested that there is an association between SIDS and an 
activated immune system.  Tumor necrosis factor (TNFα) is a multifunctional pro-
inflammatory cytokine, produced by mainly macrophages and monocytes, that is 
important in many biological processes during the immunological response . The 
TNFα gene is located at chromosome 6 in-between a cluster of other immunological 
genes, a location known to be highly polymorphic. The aim of the study was to 
investigate functional polymorphisms in the promoter region of the TNFα gene in 
order to investigate any possible associations between TNFα genotype and SIDS. 
SNPs at the position -1031T/C, -857C/T, -308G/A, -244G/A, and -238G/A were 
included. The subjects investigated in the study include 148 SIDS cases, 56 
borderline SIDS cases, 41 cases of infectious death, and 131 adult controls.  
Results: When investigating each SNP separately, associations between -238GG and 
SIDS (p=0.022) and between -308GA and borderline SIDS (p=0.005) were found. 
There were no associations between any of the other SNPs investigated. Furthermore, 
a SNP profile was constructed for each case by creating a genotype pattern from the 
investigated SNPs. Fifteen gene combinations were obtained, and four profiles had 
significantly different frequencies in SIDS cases and controls. The two SNP profiles  
-1031CT, -238GG, -857CC, -308GG and -1031TT, -238GG, -857CC, -308AA were 
found significantly more often in SIDS than in controls, and may thus be unfavorable.  
Conclusions: The findings of the study add evidence to the theory that an 
unfavorable genetic profile in the TNFα gene may be involved in SIDS. Both high 
levels and prolonged exposure to TNFα, combined with reduced release of anti- 
inflammatory cytokines, might cause a deleterious immunological imbalance in an 
infant at vulnerable developmental stage of the central nervous system and the 
mucosal immune system, and thus contribute to SIDS.  
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5.2 Paper II 
Ferrante L, Opdal SH, Vege Å, Rognum T. Cytokine gene polymorphisms and 
sudden infant death syndrome. Acta Paediatr 2010;99:384-8.  
Increased expression of the components of the mucosal immune system in SIDS has 
been reported in several studies. An unfavorable genetic predisposition in genes that 
regulate that immune response may be the cause. In this study functional SNPs in the 
genes encoding IL-6, IL-8, IL-12, IL-13, IL-16, IL-18 and IFN-γ were investigated in 
148 SIDS cases, 56 borderline SIDS cases, 41 cases of infectious death and 131 
controls.  
 
Results: Regarding genotype distribution, no differences between the investigated 
groups were found. However, in the SIDS group, the genotypes IL-8 -251AA/AT and 
IL-8 -781CT/TT were significantly more frequent in SIDS cases found dead in a 
prone sleeping position, compared with SIDS cases found dead in other sleeping 
positions. In addition, there was an association between fever prior to death and the 
genotype IL-13 +4464GG in the cases of infectious death. 
 
Conclusion: The result from this study does support the hypotheses that specific 
cytokine genotypes are a part of genetic make-up that make infants sleep prone at risk 
for SIDS. The study supports the view that SIDS is multifactorial, including both 
environmental risk factors and a predisposing inheritance pattern.  
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5.3 Paper III 
Ferrante L, Opdal SH, Vege Å, Rognum TO. IL-1 gene cluster polymorphisms and 
sudden infant death syndrome. Hum Immunol 2010; 71:402-6.  
Interleukin 1 (IL-1) is a pro-inflammatory cytokine that is of great importance for the 
organism to fight an infection. The three subgroups (IL-1α, IL-1β, and IL-1ra) of the 
cytokine are enabling transmigration of leukocytes to locations were they are needed. 
They also induce fever by re-setting the thermoregulation center. The aim of the 
present study was to investigate two polymorphisms in the IL-1α gene; a variable 
number of tandem repeat (VNTR) in intron 6 and a single nucleotide polymorphism 
in +4845G/T, as well as the -511C/T polymorphism in the gene encoding IL-1β, and a 
VNTR in intron 2 of the competitive antagonist IL-1Ra, in 148 SIDS cases, 56 
borderline SIDS cases, 41 cases of infectious death, and 131 controls. The genetic 
findings in all cases were also related to the environmental risk factors for SIDS.  
 
Results: When investigating each polymorphism separately, no differences in 
genotype distribution between the diagnosis groups and controls were found. 
However, when combining VNTR and SNP genotypes, an association between the 
gene combination IL-1α VNTR A1A1/IL-1α +4845TT and SIDS was disclosed  
(p < 0.01). In the SIDS group it was also found that the genotypes IL-1β -511CC/CT 
were significantly more frequent in the SIDS victims found dead in a prone sleeping 
position, compared with SIDS victims found dead in other sleeping positions  
(p = 0.004).  
 
Conclusions: The findings in the present study indicate that specific interleukin gene 
variants may be a predisposing factor for sudden unexpected infant death. A specific 
VNTR/SNP combination was found more often in SIDS cases compared to controls, 
and one may speculate that this genotype combination may cause an elevated 
expression of IL-1 that might be unfavorable.   
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5.4 Paper IV 
Ferrante L, Opdal SH, Vege Å, Rognum TO. Is there any correlation between 
HLA-DR expression in laryngeal mucosa and interleukin gene variation in 
sudden infant death syndrome?  Submitted  
 
Abstract: 
The mucosal immune system and the interleukin cascade are activated in a large 
proportion of SIDS cases, and SIDS victims with high IL-6 levels in the cerebrospinal 
fluid (CSF) have had clinical signs of a cold prior to death and show intense HLA-DR 
expression in laryngeal mucosa. It is thus hypothesised that SIDS might be due to an 
uncontrolled cytokine storm induced by slight infection, and that a certain genetic 
make-up pre dispose to such overreaction. In this paper, the intensity of HLA-DR 
expression in laryngeal mucosa in SIDS was studied and related  to cytokine gene 
polymorphisms as well as CSF levels of IL-1α, IL-1β, IL-6, IL-10 and TNFα.  
Laryngeal sections from 97 SIDS cases were stained with a mouse antihuman HLA-
DR monoclonal antibody, and HLA-DR expression (intensity and extensiveness of 
the staining) was scored according to a semiquantitative scoring system.  
 
Results: In 7% of the SIDS victims intense HLA-DR expression in the laryngeal 
mucosa was seen, whereas 30% were negative. HLA-DR expression was compared 
with polymorphisms previously published for the same SIDS population. Ninety-six 
percent of the cases with little or no HLA-DR expression had the two most common 
IL-1α intron 6 VNTR genotypes A1A1 and A1A2, while 67% of the cases in with 
intense and extended HLA-DR were observed to have the less frequent genotypes 
(A2A2, A3A3, A1A3, A1A4, A3A4) (p=0.04). Also, IL-6 levels in CFS were found 
to be elevated in infants with high HLA-DR score, whereas a tendency to an inverse 
relationship was seen for IL-1α.  
 
Conclusion: The results support the hypothesis of a fatal triangle in SIDS. During the 
vulnerable developmental period certain cytokine variants may predispose to an 
immunological overreaction to an otherwise harmless event, e.g. a common cold.  
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6 General discussion  
The four papers included in this thesis are the results of genetic studies of functional 
polymorphisms in cytokine genes and their possible associations with characteristic 
features found in SIDS victims and cases of infectious death. The studies also relates 
the different genetic patterns to known environmental risk factors for SIDS. The  
most important aim of this thesis is to search for predisposing factors according to the 
hypothesis of the fatal triangle for SIDS (76, 130, 131).  
 
6.1 Selection of genetic variations 
Several studies have investigated genetic variants in genes involved in the immune 
system in SIDS cases (50, 119, 122, 132). The focus of this thesis is the cytokine 
network and genetic variations in cytokine genes. Polymorphisms known to affect 
gene expression and to be associated with various infectious diseases were selected 
(86, 90, 101, 133-139). The investigated polymorphisms are all normal gene variants, 
and thus not the cause of death by themselves.  
 
6.2 Methodological challenges 
There are numerous high throughput SNP genotype technologies available, and each 
study design will have its very own requirements to the combination of technology, 
accuracy, high-throughput, low-cost identification of genetic variations. The 
Sequenom MassArray platform provides the user with accurate and cost effective 
genotyping accomplished by a homogeneous reaction format,  where allele-specific 
products with distinct masses are produced by single extension primers. Furthermore,  
multiplexed PCR reactions, a single termination mix and universal reaction conditions 
for all SNPs, small reagent volumes, and a high throughput gives high quality 
genotyping results.  
The technology provides an automated software that designs primers for the 
multiplex assay. The program is designed to avoid any primer combinations that 
could provide complications in the reaction mix, such as nonspecific extensions.  The 
considered software have shown the ability to primer design for more than 95% of the 
SNPs reported and registered on dSNP. The result of poor primer design could be 
47 
 
false positive results. To avoid this the platform offers a RealSNP software that are 
developed to scan the sequence for the possibility of any unintended products.   
The method have several pre-analytical steps that need critical considerations. A 
conservative repeat masking may  introduce some challenges in primer design 
process, if the sequence is masked too heavily the possibility to design a steady 
primer would be limited. However, there are ways to get around analytical challenges 
in the primer design programs, so that the SNPs may be multiplexed despite heavy 
repeat mask. 
Another pitfall concerning the Sequenom platform is the possibility that one or 
more of the SNPs in a multiplex does not produce results of sufficient quality. One 
possibility is to re-run the chip, this is however time consuming and will result in an 
unnecessary additional high cost in relation to the obtained analytical data.    
Should it not be possible to design appropriate primers for a multiplex analysis, 
alternative analytical procedures, such as TaqMan technology, allele specific PCR, 
and restriction fragment analysis, may be considered in order to obtain genotyping. 
TaqMan technology was chosen in this study for the SNP TNFα -1031 (rs 1799964), 
which was surrounded by a DNA sequence of such a character that a multiplex 
MassArray was not possible. TaqMan technology have been developed by Applied 
Biosystems (ABI) and allows detection of SNPs with high accuracy. The TaqMan 
probes are a based on the nuclease activity of the 5’-3’ of the enzyme Taq-polymerase 
and fluorophore-based detection.  
The TaqMan assay is a robust and high throughput analytical tool, however there 
are also some challenges that need to be addressed. The sample might fail to cluster 
with one specific allele. One likely explanation for this could be that the reporter dye 
were not assigned correctly. This will require a reset of the dye settings and 
reanalyzing of the plate. If one of the samples has a different DNA concentration than 
the rest of the samples in the same plate, problems can occur with assigning a cluster. 
Due to this sensitivity of the method one has to make sure that all the samples are 
quantified accurately and diluted to similar concentration. Another commonly 
occurring problem is the presence of bubbles in the wells. These are easily discovered 
during the last step of sample set up and avoided by centrifuging the plates. If a 
sample does not contain the correct reaction volume, which may happen during pre-
PCR, this might also give rise to an analytical problems. Should a sample not 
generate a fluorescence signal, this may be due to several factors. The sample may 
48 
 
not contain any DNA, which can be tested by quantifying the sample. Furthermore, 
the sample may contain an inhibitor, or the absence of the signal could be due to rare 
allelic variants. In the latter case the sample must be rerun using a different genetic 
analytical method.  
Another alternative approach is to sequence the DNA fragment that contains the 
SNP of interest. This may be done to verify the genotype if high quality results are 
not achieved by other analytical methods. However, direct sequencing is both a time 
consuming and a relatively expensive analytical method, but it confirms the true 
genotype with a high degree of accuracy. In the present thesis, direct sequencing was 
used to confirm the genotyping of TNFα -244 A/G (rs673). Several other genotyping 
techniques could have been used, such as molecular beacon, and scorpion assay 
which are both plate based PCR methods, as well as pyrosequencing or chip based 
technology. Sequencing was chosen due to the highly polymorphic sequences 
surrounding the SNP TNFα -244, making it an analytical challenge to design primers 
that would be stable enough.  
Several large genome-wide association studies (GWAS) have been performed on 
subjects with different diseases, to reveal genetic associations that are difficult to 
uncover with other analytical approaches. The reason is probably due to the fact that 
in several diseases, inheritance or predisposition may be polygenetic, and thus be 
caused by many different genetic variations in concert. To perform genome wide 
association studies on SIDS cases does introduce several challenges. The SIDS 
population has to be very large in order to obtain reliable data. To our knowledge 
such a large sample group does not exist as one pure population. One possible 
approach would be to pool different SIDS populations into one large study-
population, and by doing so, expanding the number of cases quite drastically. 
However, this approach does inflict new challenges as there most likely will be  
different  ethnicities in such a pooled multifactorial population. This is a major 
problem, since most gene variants differ in frequency between different ethnic 
populations.  
Another challenge is that the diagnostic criteria applied in SIDS diagnostic may 
vary considerably between countries and even between different forensic 
pathologists. Blind reevaluation of cases diagnosed as SIDS has disclosed striking 
discrepancies between the original diagnosis and reevaluated diagnoses (58, 140). 
Several researchers and forensic pathologists have put a lot of effort into reaching a 
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consensus on definition and diagnostic criteria (9, 56, 141, 142). Participants of 
international workshops and symposiums have discussed the diagnostic criteria in 
order to reach an agreement (26, 125), but have still not completely succeeded. These 
circumstances make it necessary to raise critical questions towards multinational 
consortia performing GWAS in SIDS.  
In the present thesis SIDS case, borderline SIDS cases and cases of infectious 
death were obtained from the SIDS biobank of the Institute of Forensic Medicine, 
University of Oslo. This biobank contains samples gathered and stored since 1984. 
The diagnosis are based on the Nordic criteria for SIDS (26, 58). The adult controls 
were taken from the approved control biobank.  
Most of the samples gave good analytical results.  From evaluation of the raw data 
of the MassArray it is clear that the SNP genotyping has in general been a success. 
The results indicate a robust SNP assay and good quality DNA samples.   
 
6.3 Multiple comparisons 
Many genetic studies, especially genome wide association studies, generate several 
apparently significant p-values, and the interpretation of the results is thus a 
challenge. Tests of significance most often operate with a 0.05 level, which is a level 
of significance accepted by the scientific community. This imply that the probability 
of observing the results when there is no effect, that is to falsely reject the null 
hypothesis, is less than 5%. When making many calculations on the same dataset one 
would expect to obtain significant p-values just by chance in one out of twenty 
comparisons. Consequently, when the result is based upon many calculations the 
interpretation should be made with caution. The p-values reported in the papers 
included in this thesis were a result of testing hypotheses with regard to possible 
relationships between different genotypes, cause of death, and environmental risk 
factors for SIDS.  
There are different methods for adjusting for multiple comparisons, and some are 
more conservative than others. The most commonly used is the Bonferroni correction 
(143). This test simply multiply the p-values by the number of comparisons. For a 
small number of comparisons (up to five) it’s use is reasonable, but for larger 
numbers it is highly conservative.  An alternative to Bonferroni test is the False 
Discovery Rate (FDR) method, which estimates how many of the nominally 
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significant associations that represent true findings (144). This method does not rely 
on cutoff-values, but estimates how many of the association tests reaching a given 
significance level are expected to be false. Other alternatives are Newman-Keuls, 
Duncan and Scheffe. Each method is aimed at controlling the overall Type I error rate 
at no more than 5%. The disadvantage of all these methods is that they are 
conservative, in that they err on the side of safety (non-significance) (145).  
In this thesis we have applied the Monte Carlo correction in comparisons that 
involved a large number of small groups, and the limit of the significance was set to 
0.025.  Apart from that, we have not done any adjustments for multiple comparisons. 
Since we have tested selected genes, based on knowledge of their function, such an 
approach may lead to fewer errors of interpretations (146).  
 
6.4 Hardy Weinberg equilibrium    
The Hardy Weinberg principle claims that the genotype and allelic frequencies in a 
population remains in equilibrium. To meet the requirements for the Hardy Weinberg 
equilibrium  one has to assume random mating, suppose that mutations does not 
occur, and that there is no migration of alleles between populations. The equilibrium 
can be disturbed by natural selection, genetic drift and genetic flow. A population is 
in Hardy Weinberg equilibrium (HWE) when it meets all these requirements, 
however the equilibrium is impossible in nature, as it describes an idealized state.  
The HWE is given as the following equation : p2 + 2 pq + q2 = 1, were p is the 
frequencie of the A allele in a population and q is the frequencie of the a allele.  
In order to verify the quality of the control groups, a HWE test may be performed. 
The Hardy-Weinberg equilibrium test on the SNPs included in this thesis was 
performed using a web-based Hardy-Weinberg equilibrium calculator 
(www.oege/org/software/hwe-mr-calc.shtml) (147). All the SNPs included in this 
thesis was found to be in Hardy Weinberg equilibrium in the controls.   
  
6.5 Inter- and intraobserver variation in the histopathological 
evaluation 
Evaluation of histological and immunohistochemical features are by nature 
subjective. In scientific investigation it is therefore necessary to perform inter- and 
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intra- observer variation testing. To be able to assess interobserver agreement in 
scoring HLA-DR expression in laryngeal mucosa, the histological slides of 97 SIDS 
cases were evaluated independently by the research fellow (LF) and by a forensic 
pathologist (ÅV) with experience in clinical pathology and medical microbiology. 
The identity of the histological sections was blinded for both the research fellow and 
the forensic pathologists. The scoring categories was agreed upon prior to the 
evaluation. The intraobserver agreement was assessed by the research fellow (LF) on 
blinded sections 3 months after the first evaluation. The calculated kappa value was 
well within satisfactory limits. Modern scientific histological and 
immunohistochemical studies require testing of inter- and intra- observer 
reproducibility and reproducibility studies are now mandatory (148).  
 
6.6 The fatal triangle  
Different models (figure 8) have been put forward to explain the mechanism leading 
to SIDS.  Valdes-Dapena proposed SIDS as a bi-phasic phenomenon. Before birth the 
infant is subjected to a variety of adverse intrauterine influence e.g. maternal 
smoking. After birth the infant is challenged by some external or internal factors or 
“trigger” events which he or she cannot cope, for instance an upper respiratory 
infection (149). However, already in 1972 Wegewood had proposed a triple risk 
model for SIDS (150). The models referred to in this thesis; the fatal triangle 
proposed by Rognum and Saugestad (76), as well as the triple risk model of Filiano 
and Kinney (131), and the multifactorial  model of Kahn (151), are essentially the 
same. The models suggest firstly that the infant is in a particular vulnerable 
developmental stage during the first months after birth when the central nervous 
system,  as well as the immune system, undergo rapid development.  Secondly, there 
are predisposing factors such as an unfortunate “genetic make up” or scares in the 
brainstem. The last corner in the triangle are trigger event such as slight infections, 
prone sleeping, maternal smoking, and overheating, either separately or in 
combination.       
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The tripple risk model for SIDS
Filiano JJ, Kinney  HC, Biology  of the 
Neonate 1994; 65: 194-197
Rognum TO, Saugstad OD. Acta Pædiatr Suppl 1993; 389: 82-85 Kahn A Groswasser J, Kelmanson I. In: Sudden 
Infant Death Syndrome. New Trends in the
Nineties. Ed. TO Rognum. Scandinavian University  
Press 1995: pp 132-137
 
Figure 8: The different versions of the triple risk model for SIDS (76, 131, 151).  
 
The vulnerable developmental stage. Three months after birth primitive reflexes 
such as turning the face away if mouth and nose are covered, have disappeared, and 
the infant has not yet developed experience to react rationally to such obstacles of the 
upper airways. This “reflex” chaos may constitute increased vulnerability. 
Furthermore, during the past months after birth the mucosal immune system 
undergoes an extremely rapid development.  This fact is demonstrated for the 
secretory immune system and HLA-DR in the intestinal mucosa and salivary glands 
(63, 65, 76, 152)   
Predisposing factors (figur 9), e.g. genetic variants that imply unfavorable conditions 
may affect the infant in an unfavorable manner. A single gene or mutation causing 
SIDS has still not been found, but genetic risk factors that predispose to SIDS 
together with other factors most probably exists (53). 
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Figure 9: Possible causes of sudden unexpected infant death. A little less than half of 
the cases are most likely due to different conditions that cause death by themselves, 
such as MCAD deficiency and other fatty acid oxidation (FAO) defects (41-49), long 
QT-syndrome (55, 153-158), other arrhythmias, including defects in the genes 
encoding α-syntrophin (159), nitric oxide synthase 1 adaptor protein gene (NOS1AP) 
(160), caveolin-3 (CAV-3) (157, 161), glycerol-3-phosphate dehydrogenase 1-like 
gene (GPD1-L) (162) and ryanodine receptor RyR2 (163), and hypoglycemia caused 
by defects in the gene encoding the glucose-6-phosphate transporter (G6PT1) (164). 
The other cases are genuine SIDS, with genetic factors that may predispose to death 
in combination with external risk factors. These includes genes involved in the 
immune system, including IL-1, IL-6, IL-8, IL-10, TNFα, and complement component 
C4 (50, 52, 115, 117, 165-168), genes involved in brain development and function, 
including the genes encoding aquaporin 4 (AQP4), the human fifth Ewing variant 
(FEV), pituitary adenylate cyclase activation peptide (PACAP), paired like homeobox 
(PHOX) 2B, tyrosine hydroxylase (THO1) and the sodium/proton exchanger NHE3 
(169-175), the serotonin transporter 5-HTT (176-179), and flavin monooxygenase 3 
(FMO3), which is a gene involved in detoxification processes (180).  
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The trigger events that have got most attention since 1988 are prone sleeping, 
overheating and maternal smoking. After the “back to sleep” campaign in the late 
eighties and early nineties the SIDS rate have dropped dramatically. However, prone 
sleeping still remains a serious risk factor and more than 50% of the infants over 2 
months are found prone sleeping (181). There are many hypothesis with regard to 
possible death mechanisms related to prone sleeping, e.g. suffocation due to 
positional asphyxia or rebreeding of carbon dioxide. The final proofs remain to be 
disclosed. 
 From epidemiological investigations as well as from studies on SIDS victims, it 
seems reasonable to assume that SIDS deaths occur as a result of three factors: a 
vulnerable developmental stage, predisposition, such as genetic risk factors and 
finally environmental factors that may act as triggers. When searching for patterns of 
genetic variants of significance, one is faced with a methodological challenges, one of 
these is the problem of multiple comparisons. This challenge is discussed in the 
following section.  
 
6.7 Cytokine gene polymorphisms and its possible role in SIDS  
The most likely candidates for explaining fatal vulnerability to ordinary harmless 
infections in SIDS, are the cytokine genes. The immune response is regulated by the 
cytokines and the presence and concentration of the different cytokines determine the 
duration and intensity of the immune response. The associations uncovered in this 
thesis between different polymorphisms and SIDS and environmental factors for 
SIDS, most likely represents only a small part of genetic patterns that may result in an 
unfortunate immunological reaction. The cytokine network is extremely complex and 
their study in deceased utmost complex. It is not possible to compare cytokine 
concentrations in dead subjects with levels measured in live patients. However, the 
stability of the cytokine concentration in CSF after death, is tested by performing 
several samplings in the post mortem period (60). These examination show that the 
concentrations partly increase after death, partly decrease. The median value was 
however fairly stable.   
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7 Conclusion  
The present thesis indicates that there exists a predisposition for SIDS due to genetic 
variation in the cytokine network. Combined with environmental risk factors and a 
vulnerable developmental stage of the infant, this may be fatal. This means that a 
genetic predisposition by no means implies that SIDS will ensue. Most multifactorial 
diseases and conditions are not caused by just one unfortunate gene variation.  
Therefore, the development of multiplex chip analysis is becoming more and more 
important in research into genetic diseases. Although new knowledge has been 
obtained through the present studies, they also point to challenges of how to proceed 
in mapping genetic risk factors for SIDS. Last, but not least, we need to learn how to  
transform the knowledge into prevention of SIDS deaths. To sum up the conclusions 
for the thesis:  
 
1. An unfavorable genetic profile in the TNFα gene may be involved in SIDS, by 
exposing the infant to both a high level of and a prolonged exposure to TNFα.  
2. Genetic variation in the genes encoding IL-8  and IL-1β are a part of a genetic make-
up that make infants sleeping prone at risk for SIDS.  
3. Genetic variation in the IL-1 gene cluster may also contribute to SIDS, by giving a 
changed expression of both IL-1α and IL-1β and thus a disturbance in the 
immunological response.  
4. SIDS cases with HLA-DR activation in laryngeal mucosa more often have rare 
genotypes of IL-1α, further strengthening the finding of an involvement of IL-1 in 
SIDS.  
5. Taken together, the findings in this thesis indicate that specific interleukin gene 
variants may be predisposing factors for sudden unexpected infant death.  
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9 Errata  
1 Page 7 “that large a thymus” to “that a large thymus”  
 
2 Page 10: text on the Y axis “ No of deaths pr 1000 live births” 
 
3 Page 15: “SPA” to “SP-A”  
 
4 Page 20: move “–“ to next line 
 
5 Page 21: move “–“ to next line 
 
6 Page 21: move “IL-“ to next line 
 
7 page 28: “was created” to “will be created” 
 
8 page 35: remove the red underscore from “IFNγ”  
 
9 Page 35: change “IFNγ” to “IFN-γ” 
 
9 Page 37: move “3’ ” to next line 
 
10 Page 43: change “IL-1α VNTR A1A1/IL-1β+4845TT” to  IL-1α VNTR A1A1/IL-
1α+4845TT 
 
11 There is an error in the dissertation sent to the medical faculty in my article “Is 
there any correlation between HLA-DR expression in laryngeal mucosa and 
interleukin gene variation in sudden infant death syndrome?”were the 
illustration of a negative scored larynx was changed before submitted to the 
journal. This was regretfully not changed in the article that followed the 
dissertation. The illustration figure 1 a in the paper is changed to the same 
illustration as followed the submitted paper.   
 
12 Double space at several location in the manuscript to single space.  
 
13 No space after “period”  to one space.  
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